<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640625</url>
  </required_header>
  <id_info>
    <org_study_id>REK 2015/2125</org_study_id>
    <nct_id>NCT02640625</nct_id>
  </id_info>
  <brief_title>Improving Prognosis in HIV Infection</brief_title>
  <official_title>Adjuvant Mucosal Therapy in HIV-infected Men With Insufficient Response to Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety of probiotics in cART-treated
      immunologic non-responder (INR) patients with chronic HIV infection.

      The secondary objectives are to i) explore the biological effects of probiotics in combined
      antiretroviral therapy(cART)-treated INR patient with chronic HIV infection, and ii)
      investigate differences between cART-treated HIV-infected INR and non-INR patients with
      regards to gut microbial composition and mucosal barrier function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>10 weeks</time_frame>
    <description>Number of Participants who Experienced Adverse Effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delta HIV Viral Load</measure>
    <time_frame>8 weeks</time_frame>
    <description>Unit og Measure: copies/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delta Blood CD4 Count</measure>
    <time_frame>8 weeks</time_frame>
    <description>Unit of Measure: cells/microL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alteration in Gut Microbiota Composition</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative (Unit of Measure: Descriptive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in Epithelial Gene Expression</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative (Unit of Measure: Descriptive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in Lamina Propria T Cell Subsets</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative assays on T cell subsets distribution and function (Unit of Measure: Frequency)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in Systemic T Cell Intracellular Signaling</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative assays on T cell receptor signaling mechanism (Unit of Measure: Frequency)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alterations in Systemic Markers of Immune Activation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Explorative assays on soluble inflammation markers and lymphoid cells activation status (Unit of Measure: Descriptive)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Probiotic compound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic compound</intervention_name>
    <description>Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.</description>
    <arm_group_label>Probiotic compound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV seropositive &gt;4 years.

          -  Continuous combined antiretroviral treatment (cART) &gt;4 years.

          -  Plasma HIV RNA &lt;50 copies/mL &gt;3,5 years.

          -  Cluster of differentiation(CD)4+ T cell count &lt;400 cells/µL (OR &gt;600 cells/µl) &gt;3.5
             years.

          -  Caucasian

          -  Signed informed consent and expected cooperation of the patients for the treatment and
             follow up must be obtained and documented according to International Committee on
             Harmonization (ICH) Good Clinical Practice (GCP), and national/local regulations.

        Exclusion Criteria:

          -  Plasma hepatitis C (HCV) RNA positive.

          -  Serum hepatitis B surface antigen (HBsAg) positive.

          -  Comorbidity of inflammatory bowel disease, coeliac disease or malnutrition.

          -  Concomitant use of non-steroid anti-inflammatory drugs (NSAID), corticosteroids,
             disease-modifying antirheumatic drugs, or other anti-inflammatory pharmaceutical
             substances.

          -  Concomitant use of antithrombotic pharmaceutical substances

          -  Regular (weekly) use of any probiotic substance within 3 months prior to inclusion.

          -  Use of antibiotics within 3 months prior to inclusion.

          -  Deranged liver function (serum albumin &lt;25 g/L or Child-Pugh ≥10)

          -  Renal failure (estimated glomerular filtration rate (eGFR) &lt;30 ml/min)

          -  Heart failure (NYHA class II-IV)

          -  Intolerance to milk or phenylalanine

          -  Any reason why, in the opinion of the investigator, the patient should not participate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dag Henrik Reikvam, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital (Ullevaal campus)</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <results_first_submitted>November 8, 2017</results_first_submitted>
  <results_first_submitted_qc>March 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2020</results_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Dag Henrik Reikvam</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Mucosal immunology</keyword>
  <keyword>Gut biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02640625/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Probiotic Compound</title>
          <description>Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
Probiotic compound: Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Probiotic Intervention</title>
          <description>HIV positive on cART &gt;4 years with CD4 &lt;400 cells/ml and HIV RNA &lt;50 copies/ml</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="38" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBsAg negative AND HCV RNA negative AND no gastrointestinal disorders</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Effects</title>
        <description>Number of Participants who Experienced Adverse Effects</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Probiotic Intervention</title>
            <description>HIV positive on cART &gt;4 years with CD4 &lt;400 cells/ml and HIV RNA &lt;50 copies/ml</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <description>Number of Participants who Experienced Adverse Effects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Delta HIV Viral Load</title>
        <description>Unit og Measure: copies/mL</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Probiotic Compound</title>
            <description>Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
Probiotic compound: Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.</description>
          </group>
        </group_list>
        <measure>
          <title>Delta HIV Viral Load</title>
          <description>Unit og Measure: copies/mL</description>
          <units>copies/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Delta Blood CD4 Count</title>
        <description>Unit of Measure: cells/microL</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Probiotic Compound</title>
            <description>Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
Probiotic compound: Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.</description>
          </group>
        </group_list>
        <measure>
          <title>Delta Blood CD4 Count</title>
          <description>Unit of Measure: cells/microL</description>
          <units>cells/microL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="-372" upper_limit="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alteration in Gut Microbiota Composition</title>
        <description>Explorative (Unit of Measure: Descriptive)</description>
        <time_frame>8 weeks</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alterations in Epithelial Gene Expression</title>
        <description>Explorative (Unit of Measure: Descriptive)</description>
        <time_frame>8 weeks</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alterations in Lamina Propria T Cell Subsets</title>
        <description>Explorative assays on T cell subsets distribution and function (Unit of Measure: Frequency)</description>
        <time_frame>8 weeks</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alterations in Systemic T Cell Intracellular Signaling</title>
        <description>Explorative assays on T cell receptor signaling mechanism (Unit of Measure: Frequency)</description>
        <time_frame>8 weeks</time_frame>
        <posting_date>11/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alterations in Systemic Markers of Immune Activation</title>
        <description>Explorative assays on soluble inflammation markers and lymphoid cells activation status (Unit of Measure: Descriptive)</description>
        <time_frame>8 weeks</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Probiotic Intervention</title>
          <description>HIV positive on cART &gt;4 years with CD4 &lt;400 cells/ml and HIV RNA &lt;50 copies/ml</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cholecystitis with E. coli bacteremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dag Henrik Reikvam</name_or_title>
      <organization>Oslo University Hospital</organization>
      <phone>+4722119881</phone>
      <email>dagrei@ous-hf.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

